Tixagevimab
Modify Date: 2025-09-04 00:24:20
Tixagevimab structure
|
Common Name | Tixagevimab | ||
|---|---|---|---|---|
| CAS Number | 2420564-02-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TixagevimabTixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor[1]. |
| Name | Tixagevimab |
|---|
| Description | Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Tixagevimab 可以与 Cilgavimab 组合，形成 AZD7442，AZD7442（2，4 或 16 mg/kg，静脉注射）在感染 G61 菌株的仓鼠以及在感染了 Omicron 变种的仓鼠中，可以导致肺部感染滴度和病毒 RNA 水平呈剂量依赖性下降，且与 2 mg/kg 剂量的动物相比，16 mg/kg 剂量的感染滴度显著降低[2]。 |
| References |
| No Any Chemical & Physical Properties |